Using whole blood samples of advanced melanoma, patients who did not respond to anti-PD-1 and/or anti-CTLA-4 had decreased cDC1 number and function at every time point after treatment, whereas responding patients showed similar levels of cDC1 pre-treatment and at the time they showed clinical response. This evidence concerns the gene PDCD1 and melanoma.